Monthly shot study tests better doses for opioid addiction
NCT ID NCT04995029
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two different doses (100 mg vs 300 mg) of a monthly buprenorphine injection in 785 adults with moderate to severe opioid use disorder. The goal was to see which dose helped people stay in treatment and reduce opioid use. The study also compared a faster versus standard way to start the medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Accel Research Sites- Lakeland Clinical Research Unit
Lakeland, Florida, 33803, United States
-
Alpine Research Organization
Clinton, Utah, 84015, United States
-
Artemis Institute for Clinical Research
San Diego, California, 92103, United States
-
Asclepes Research Centers
Panorama City, California, 91402, United States
-
Bay Pines VA Healthcare System
Bay Pines, Florida, 33744, United States
-
Behavioral Clinical Research, Inc
Miami Lakes, Florida, 33016, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Carolina Medical Research, LLC
Clinton, South Carolina, 29325, United States
-
Carolina Medical Research, LLC
Greenville, South Carolina, 29607, United States
-
Center For Emotional Fitness
Cherry Hill, New Jersey, 08002, United States
-
Centre for Addiction and Mental Health
Toronto, Ontario, M6J 1H4, Canada
-
Clinical Neuroscience Solutions, Inc
Orlando, Florida, 32801, United States
-
Clinical Research Associates of Central PA
Altoona, Pennsylvania, 16602, United States
-
Collaborative Neuroscience Network, LLC
Garden Grove, California, 92845, United States
-
David Weitzman
Myrtle Beach, South Carolina, 29577, United States
-
Duke Hospital
Durham, North Carolina, 27705, United States
-
Hassman Research Institute
Berlin, New Jersey, 08009, United States
-
ICAHN School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Innovative Clinical Research Inc.
North Miami, Florida, 33161, United States
-
Insite Clinical Research
DeSoto, Texas, 75115, United States
-
Midwest Clinical Research
Dayton, Ohio, 45417, United States
-
Monroe Biomedical Research
Monroe, North Carolina, 28112, United States
-
Pahl Pharmaceutical Professionals LLC
Oklahoma City, Oklahoma, 73112, United States
-
Prisma Health ITOR Research Pharmacy
Greenville, South Carolina, 29605, United States
-
Progressive Clinical Research
Bountiful, Utah, 84010, United States
-
SP Research, PLLC
Oklahoma City, Oklahoma, 73112, United States
-
Sarkis Clinical Trials
Gainesville, Florida, 32607, United States
-
Today Clinical Research
Oklahoma City, Oklahoma, 73120, United States
-
Unity Clinical Research
Oklahoma City, Oklahoma, 73118, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.